

COVID -19: could green tea catechins reduce the risks?

Maksim Storozhuk

Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

Corresponding author

Dr. M. Storozhuk

Bogomoletz Institute of Physiology, National Academy of Science of Ukraine

4 Bogomoletz Street

Kiev 01024

Ukraine

Tel.: +380 44 2562052

Fax: +380 44 2536458

e-mail: maksim@biph.kiev.ua

Abstract

Purpose: Several lines of emerging pharmacological and epidemiological evidence imply that overall risks related to COVID-19 may be reduced by green tea catechins. Therefore, it may be expected that countries with higher per/capita green tea consumption would be less affected by COVID-19. The aim of this study was to assess this possibility.

Methods: Among countries with at least 3 million population (n=134), countries with relatively high (above 150 g) per/capita green tea consumption have been identified (n=21); (ii) normalized to population values of COVID-19 cases (morbidity) and deaths (mortality) for groups of countries with high and low per/capita green tea consumption were compared.

Results: Striking differences in COVID-19 morbidity and mortality between groups of countries with ‘high’ and ‘low’ green tea consumption were found. The differences were still observed after the adjustment for the onset of the disease. An analysis using multiple linear regression approach suggests that the associations are present at the level of individual countries.

Conclusion: Evidence supporting the idea that green tea constituents could reduce overall risks related to COVID-19 has been obtained. The results are promising and are in line with emerging evidence from other studies including pharmacological ones. Nevertheless, because of limitations of this study the idea still should be considered as a hypothesis requiring further assessment. Several vaccines are currently validated for COVID-19 prevention and mass vaccination has already been started in many countries. Still, it is likely that the development of an efficient drug therapy that reduces COVID-19 severity/mortality would be important for rather prolonged time. In this context, the results obtained in this study may have significant implications.

Key words: catechins; SARS-CoV-2; (-)-epigallocatechin (EGC); (-)-epigallocatechin-3-gallate (EGCG).

Introduction

Several vaccines are currently validated for COVID-19 prevention and mass vaccination has already been started in some countries. Nevertheless, it is likely that development of efficient drug therapy that reduces COVID-19 severity/mortality would be important for rather prolonged time. Several lines of evidence suggest that green tea catechins (such as epigallocatechin-3-gallate (EGCG)) could give a clue to this issue. As briefly outlined below this could be due to (i) direct anti-viral activity and (ii) the influence on factors associated with COVID-19 severity and mortality.

Green tea catechins, are known to have anti-viral activity against several viruses [1-4] including viruses causing respiratory diseases [5, 6]. Recent target-based virtual ligand screening study suggests that at least one catechin (EGCG), is likely to target papain-like proteinase (PLpro), an indispensable enzyme in the process of coronavirus replication and infection of the host [7]. Inhibition of SARS-CoV-2 3CL-Protease by EGCG has been recently demonstrated *in vitro* [8].

Additionally, several factors associated with COVID-19 mortality are likely to be affected by green tea constituents. Indeed, there is evidence that green tea catechins: lower cholesterol levels [9, 10]; have anti-diabetic [11] and anti-obesity effects [12]; are beneficial in cardiovascular disease [13].

Besides, EGCG is protective in diseases with uncontrolled immune activation, thus, may ameliorate severity of COVID-19 [14] since the latter is related to overreaction of the immune system [15]. Finally, green tea catechins can act as ionophores for zinc ions, while the latter are considered as potentially beneficial in relation to COVID-19 [16, 17].

Altogether these results suggest that green tea catechins could reduce overall risks related to COVID-19. If so, it may be expected that countries with higher level of green tea consumption are less affected by COVID-19.

To address this hypothesis an ecological analysis was performed in this study. For this purpose: (i) among countries with at least 3 million population (n=134), countries with relatively high (above 150 g) per/capita green tea consumption have been identified (n=21); (ii) normalized to population values of COVID-19 cases (morbidity) and deaths (mortality) for groups of countries with high and low per/capita green tea consumption were compared.

Methods

Ethics approval and consent to participate. Not applicable (ethical approval was not deemed necessary as this was an analysis of publicly available data).

Identification of countries with relatively high per/capita green tea consumption

It has been previously reported that higher per/capita green tea consumption is typical for some countries in Asia, North Africa and Middle East [18]. Values for several countries in Asia (China, Vietnam, Japan and Indonesia) have been reported [19]. There is also information regarding Taiwan, arbitrary considered as a green tea consuming in the framework of this work because of predominant consumption of the Paochong tea (oxidized by only (8-12%) and Oolong tea (semioxidised) [20]. The value of green tea consumption in Taiwan, indicated in the Table 1 (750 g) was arbitrary estimated as equal to one half of that reported [21] for *total* tea consumption in this country. The relevant and reliable information regarding green tea consumption in the other countries is scarce [22], it is not as trivial as it may seem to find it. Therefore, to estimate the values of per/capita green tea consumption in the other countries the following approach was used. It was assumed that the difference between annual green tea import and export in a particular country (except countries with considerable green tea production) is roughly equivalent to annual

green tea consumption. Thus, the difference between import and export divided by population should give a reasonable estimate of per/capita consumption. Indeed, such an approach is used for estimation for countries that do not produce tea [22].

The information about green tea import and export for particular countries was obtained from Commodity Trade Statistics Database | United Nations Statistics Division database [23], the search was limited to records since the year 2010. Since recent records are unavailable for some countries, to minimize time bias, it was arbitrary chosen to use values for year 2016 as a standard (still for a few countries older records in the database were used in this work).

Using reported values for China, Vietnam, Japan and Indonesia [19], an estimate for Taiwan and the approach mentioned above it has been found that per/capita green tea consumption is above 150 grams in twenty one countries. However, it is essential to note that the list (Table 1) is probably incomplete (see considerations below), because the approach used for the estimate has several limitations. Namely, it cannot be excluded that some countries with considerable green tea per/capita consumption have not been identified among those producing green tea (for instance, Myanmar, South Korea, Papua New Guinea). Additionally, some countries may have not been identified because of absence of the relevant records in the UN database (for instance, Tajikistan). Finally, the estimates may be biased by import/export operations not reflected in the UN database. This is especially likely for 'smaller' import/export operations and thus for less populated countries. For this reason, detailed screening of the database was limited to countries with at least a 3 million population.

Data regarding COVID-19 morbidity and mortality

All data were obtained from open resources. Information on total number of cases and total number of deaths was obtained from ‘Worldometers info. Coronavirus’ [24]. The information on Worldometer is based on official daily reports and considered as a reliable (for instance, [25] [26]). For some comparisons, information about COVID-19 morbidity (defined as number of cases per million population) and mortality (defined as number of deaths per million population) for a specific date was directly obtained from [24]. For others, considering that the onset of the disease was not simultaneous in different countries, an adjustment for this factor was made as described below. Date when the total number of confirmed cases in a particular country became 50 (or more) was determined based on information provided in [24] and considered as a reference time point (referred further as the onset date). Then information about the total number of cases/deaths at a date eight months after the onset date was obtained from [24] and normalized to population. These adjusted values were (also) used for comparisons. Eight-month period after the onset date has been chosen as a compromise between longer period for analysis and a number of countries available for analysis (performed in January 2021). Since in some countries the onset occurred in June and even July (2020) some countries were excluded from a comparison of the *adjusted* values. Calculated values reported in the tables are (typically) rounded to an integer, while values used for statistical comparisons were not rounded.

Statistical analysis

Since the variables of COVID-19 morbidity and COVID-19 mortality do not have a normal distribution [25], non-parametric statistic was primarily employed for the analysis (as suggested in [25, 27]). Namely, Wilcoxon (Mann-Whitney U Test) for Unpaired Data and Spearman Rank Correlation were used for the analysis. On the hand, for multiple linear regression analysis, an approach similar to that previously reported [25] was used. In this analysis, morbidity and

mortality per million of population were transformed to the common logarithm (\log_{10}) to adjust for normality of the distribution as suggested previously [25].

Factors, included in multiple linear regression analysis (beside green tea consumption) were: population density [28], percentage of population aged above 65 [29], percentage of urban population [30]. In a complementary analysis an additional variable, namely Human Developmental Index (HDI) based on access to health and education services and income [31] was added to the model. 'KyPlot' software was employed for statistical assessments.

Results

A tentative list of countries with relatively high (above 150 g) per/capita green tea consumption was created using the approach described in Methods by screening relevant information for countries and territories listed in [24] and population with at least three million (134 countries and territories). Among those 21 were identified as countries with ‘high’ (above 150 g) per/capita green tea consumption (**Table 1**).

Table 1. A tentative list of countries with ‘high’ (above 150 g per/capita) green tea consumption.

Country	Per capita green tea consumption (g)	COVID-19 morbidity (per million population)	COVID-19 mortality (per million population)
1 Mauritania	3393	3386	85
2 Morocco	1783	12319	212
3 Taiwan	750	36	0.3
4 Afghanistan	719	1370	59
5 Japan	650	2449	34
6 Mali	605	379	15
7 Mongolia	552	457	0.6
8 Uzbekistan	525	2310	18
9 Libya	451	15606	239
10 Vietnam	380	16	0.4
11 Senegal	345	1319	30
12 Algeria	332	2335	64
13 China	320	61	3
14 Hong Kong	290	1262	22
15 Tunisia	247	14729	465
16 Guinea	219	1056	6
17 Niger	212	166	6
18 Burkina Faso	167	419	5
19 Indonesia	200	3259	94
20 UAE	196	25094	74
21 Denmark	178	32278	296
World ¹ (average)		18378	314

Per capita green tea consumption is a coarse estimate (see Methods for details). In relation to further analysis, information regarding COVID-19 morbidity and mortality is also provided. This information was retrieved from ‘Worldometer’ [24] as provided on January 16, 2021. World1 – refers to top 212 countries and territories (ranked by population) affected by COVID-19 according to information from ‘Worldometer’ [24] as provided on January 16, 2021.

Among the other 113 countries: in 18 the overall annual balance between import and export of green tea was negative; for 13 countries no records were found in the UN database (since year 2010).

Since information about *production* of green tea in countries with negative import/balance was not available, the group of these 113 countries was considered as a group with (i) low and (ii) undetermined consumption. Finally, a group of countries with the *estimated* consumption below 150 g was considered as a ‘low-consuming’ (n=82). Information about total number of COVID-19 cases (per one million population) and total number of COVID-19 death (per one million population) was obtained from ‘Worldometer’ [24] as provided on January 16, 2021 for the countries from the above mentioned three groups and summarized in **Table 2**.

Table 2

COVID-19 morbidity and mortality in relation to per/capita green tea consumption.

	Group 1 (countries with ‘high’ green tea consumption) N=21	Group 2 (countries with ‘low’ or undetermined green tea consumption) N=113	Group 3 (countries with ‘low’ green tea consumption) N=82	World ¹
COVID-19 morbidity	1370 (419-3386)	10056 ^{**} (930-35731)	15601 ^{**} (1213-36434)	8736
COVID-19 mortality	30 (6-85)	166 ^{**} (15-732)	286 ^{***} (26-868)	94

Values (per one million of population) are: median and interquartile range (IQR). ** (P<0.01) and *** (P<0.001) denote significance level of difference as compared to Group 1 (Wilcoxon (Mann-Whitney U Test) for Unpaired Data). Raw data for individual countries are from ‘Worldometer’ [24] as provided on January 16, 2021. World1 – refers to top 212 countries and territories (ranked by population) affected by COVID-19 according to information from ‘Worldometer’ [24] as provided on January 16, 2021.

Both, COVID-19 morbidity and mortality were strikingly (several times) lower in the Group 1 as compared to Group 2 (and Group3). Besides, the differences were highly significant (**Table 2**). These results support the hypothesis that green tea constituents could reduce overall risks related to COVID-19. On the other hand, this preliminary analysis has several limitations. In particular, the

onset of the disease was not simultaneous in different countries. To adjust for this the approach described in Method section was used.

A summary for the adjusted values is shown in **Table 3**. Notice a reduction of ‘N’ in the groups as compared to Table 2. This is due to late onset of the disease in some of the countries (values for four countries in Group 2 and two countries in Group 3 were not available at the time of analysis (January 22, 2021)). There were still profound and statistically significant differences in COVID-19 morbidity and mortality between Group 1 and Group 2/Group 3 (**Table 3**).

Table 3

Adjusted for the onset COVID-19 morbidity and mortality in relation to per/capita green tea consumption.

	Group 1 (countries with ‘high’ green tea consumption)	Group 2 (countries with ‘low’ or undetermined green tea consumption)	Group 3 (countries with ‘low’ green tea consumption)
	N=21	N=109	N=80
COVID-19 morbidity	996 (260-3433)	6767 ^{**} (894-15891)	10054 ^{***} (1077-17640)
COVID-19 mortality	18 (3-55)	109 ^{**} (15-307)	155 ^{***} (24-387)

Values (per one million of population) are: median, IQR. ** (P<0.01) and *** (P<0.001) denote significance level of difference as compared to Group 1 (Wilcoxon (Mann-Whitney U Test) for Unpaired Data). Values represent the epidemic situation eight months after the onset of the disease (see Methods for more details) for the countries with known values as of January 22, 2021.

To check for possible association between per capita green tea consumption and COVID-19 morbidity/mortality at the level of individual countries, corresponding correlation coefficients were calculated. Namely, Spearman Rank Correlation was used to calculate correlation coefficients between: (i) the *adjusted* for the onset value of morbidity (or mortality) and (ii) per capita green tea

consumption in a particular country. Thus, the total number of countries considered in this analysis was 101 (see Supplementary **Table S1**). No statistically significant correlation between green tea consumption and the morbidity was observed ($Rho=-0.12$; $P=0.22$), while there was a weak but significant correlation between estimated green tea consumption and the mortality ($Rho=-0.2$; $P=0.04$).

To further study potential associations a linear regression analysis accounting for several potential confounders was used. In this analysis: (i) morbidity and mortality per million of population were transformed to the common logarithm (\log_{10}) to adjust for normality of the distribution (as suggested in [25]); (ii) in addition to green tea consumption, factors, reported previously as important confounders were included. In regard of the latter: population density [32]; percentage of population aged above 65 [32] and percentage of urban population [25] were included. Mauritania was excluded from the linear regression analysis as the apparent outlier in terms of estimated green tea consumption. Indeed, value of 3393 g/capita is much greater than $Q3+1.5*IQR$ for the *group with high green tea consumption* (where Q3 is 3-rd quartile, IQR interquartile range), thus was considered as outlier according to Tukey's rule [33]. Additionally, since the number of deaths (per million) in Cambodia was 0 (as of January 22, 2021) and could not be transformed to the logarithm, this country was excluded from the analysis in regard of the *mortality*.

It has been found that there are: weak but statistically significant correlations between morbidity (and mortality) and green tea consumption; stronger correlations between morbidity (and mortality) and percentage of urban population. Plots for COVID-19 morbidity and mortality in relation to these two factors are shown in **Fig. 1**, additional details about results of the analysis are provided in Supplementary **Table S2 (A,B)**.




Figure 1. Percentage of urban population and per capita green tea consumption are associated with COVID-19 morbidity and mortality.

COVID-19 morbidity (A, C) and mortality (B, D) in relation to % of urban population (upper panel) and green tea consumption (lower panel). Morbidity and mortality values are adjusted for the onset of the disease (8 months after the onset). Countries with values available as of January 22, 2021 were included. Values of regression coefficient R and significance levels denoted were calculated using the multiple linear regression model, N – number of countries included in the analysis. See text for more details. On plots C and D gray circles represent values for the countries with ‘high’ green tea consumption; for some of these standard two letter country codes are provided. AF- Afghanistan; CN –China; ID – Indonesia; JP –Japan; LY- Libya; MA- Morocco; ML –Mali; MN-Mongolia; TW- Taiwan; UZ – Uzbekistan. Notice, the circle representing Indonesia in D, is almost completely overlapped with that representing UAE.

Thus, it appears that COVID-19 morbidity and mortality are indeed associated with green tea consumption at the level of individual countries. Of note, these associations were still statistically significant when additional important [32] variable, namely Human Developmental Index (HDI) based on access to health and education services and income [31] was added to the model (see Supplementary **Table S3 (A,B)**).

It has been found recently that countries with routine mass drug administration of anti-parasitic prophylactic ivermectin have a significantly lower incidence of COVID-19 [34]. This important finding is in accordance with anti-viral activity of ivermectin in vitro [35] and other related evidence [36]. Therefore, mass drug administration of ivermectin could affect associations considered in the present study as a confounder. To account for this possibility, countries with mass drug administration of ivermectin [37] were excluded from the linear regression analysis and corresponding values were recalculated. In this restricted subset of countries, the associations between COVID-19 morbidity (and mortality) and green tea consumption were still significant (Supplementary **Table S4 (A, B)**). Moreover, the strengths of both correlations became notably higher (-0.24 and -0.28) as compared to the unrestricted set of countries (-0.19 and -0.22). These results indicate that the associations between COVID-19 morbidity (and mortality) and green tea consumption are not due to an overlap of countries with higher green tea consumption with countries with mass drug administration of ivermectin. Additionally, these results indirectly support previously reported association between mass drug administration of ivermectin and lower incidence of COVID-19 [34].

Discussion

The main finding of this study is that higher green tea consumption is associated with lower COVID-19 morbidity/mortality at the level of ecological study. Indeed, there are striking differences in COVID-19 morbidity/mortality between groups of countries with ‘high’ and ‘low’ green tea consumption. The differences were still observed after the adjustment for the onset of the disease. Besides, the analysis using multiple linear regression approach suggests that the associations are present at the level of individual countries. At this level, this is presumably the first evidence supporting the idea that green tea constituents may reduce the risks related to COVID-19. These results are in agreement with several lines of emerging evidence implying that green tea catechins may be effective in prevention/treatment of COVID-19 or amelioration of its severity ([7-11, 14]) (as outlined in the Introduction). Nevertheless, in the context of this study, it would be fair to mention that green catechins are not *the only* constituents of green tea. Other constituents may also be of importance for potential beneficial effects.

Limitations of the study and potential future directions. For most of the countries green tea consumption was estimated based on the annual balance between its import and export. Although this approach is used for coarse estimates [22], apparently, it has several limitations as outlined in Methods. Thus, the list of countries with ‘high’ green tea consumption should be considered as a tentative. It cannot be excluded that some countries with considerable green tea per/capita consumption have not been identified among those producing green tea (for instance, Myanmar, South Korea, Papua New Guinea). It would be of interest to obtain relevant information in regard of these countries, include it in the analysis and check how this would affect associations considered in this work.

Other limitations include multiple factors that may differentially affect COVID-19 morbidity and mortality in distinct countries. For instance: the administrative strategies to prevent transmission; population density, percentage of urban population, percentage of older population; condition-specific mortality risks; TB infection and BCG vaccination [25, 27, 38]. Potential role of only some of these factors was assessed in this study. On the other hand, potential confounding factors included in the linear regression model in this study represent the majority of these identified as *consistent* (and at the same time relatively independent) in relation to COVID-19 in previous studies [25, 32]. Additionally, it appears that there are *causal* relations between green tea consumption, and several condition-specific risks (such as risks of cardiovascular diseases [13], diabetes [11], etc). Therefore, inclusion of these risk factors in the regression model *as confounders* would be rather controversial because a confounding variable should be an independent factor for the outcome of interest [39]. It is important to notice that results of any ecological study, taken alone, could only provide the information about a correlation rather than a causal relation. Thus, experimental studies are required to either confirm or reject the potential causal relation. Importantly, green tea catechins are considered as safe by FDA and have been already investigated in experimental studies in relation to some infections. Moreover, results of at least one *randomized placebo-controlled* study [40] strongly suggest that green tea catechins can protect against acute upper respiratory tract infections thus, quite likely, infections induced by members of coronavirus family. Therefore, it may be expected that green tea catechins can also protect against the infection induced by SARS-CoV-2. If this is the case, it would have important implications. Possible efficacy of green tea catechins in treatment of COVID-19 and amelioration of its severity should be also assessed in observational and experimental epidemiological studies as potentially even more important.

Conclusion.

Evidence supporting the idea that green tea constituents could reduce overall risks related to COVID-19 has been obtained. The results are promising and are in line with emerging evidence from other studies including pharmacological ones. Nevertheless, because of limitations of this study the idea still should be considered as a hypothesis requiring further assessment. Several vaccines are currently validated for COVID-19 prevention and mass vaccination has already been started in many countries. Nevertheless, it is likely that development of efficient drug therapy that reduces COVID-19 severity/mortality would be important for rather prolonged time. In this context, the results obtained in this study may have significant implications.

Declarations section

Ethical Approval and Consent to participate

Not applicable

Consent for publication

Not applicable

Availability of supporting data

Data (mostly) available within the article or its supplementary materials. Additional data available on request from the author.

Competing interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

I would like express my gratitude to personnel of the open resources for creating excellent opportunities for research.

References

- 1 Xu J, Xu Z, Zheng W. A Review of the Antiviral Role of Green Tea Catechins. *Molecules* 2017;22(8) <https://doi.org/10.3390/molecules22081337>
- 2 Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review. *Phytomedicine* 2020;153286 <https://doi.org/10.1016/j.phymed.2020.153286>
- 3 Ghrairi T, Jaraud S, Alves A, Fleury Y, El SA, Chouchani C. New Insights into and Updates on Antimicrobial Agents from Natural Products. *Biomed Res Int* 2019;2019:7079864 <https://doi.org/10.1155/2019/7079864>
- 4 Reygaert WC. Green Tea Catechins: Their Use in Treating and Preventing Infectious Diseases. *Biomed Res Int* 2018;2018:9105261 <https://doi.org/10.1155/2018/9105261>
- 5 Furushima D, Ide K, Yamada H. Effect of Tea Catechins on Influenza Infection and the Common Cold with a Focus on Epidemiological/Clinical Studies. *Molecules* 2018;23(7) <https://doi.org/10.3390/molecules23071795>
- 6 Nanri A, Nakamoto K, Sakamoto N, Imai T, Mizoue T. Green tea consumption and influenza infection among Japanese employees. *Eur J Clin Nutr* 2020 <https://doi.org/10.1038/s41430-020-00792-3>
- 7 Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B* 2020 <https://doi.org/10.1016/j.apsb.2020.02.008>
- 8 Jang M, Park YI, Cha YE, Park R, Namkoong S, Lee JI et al. Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro. *Evid Based Complement Alternat Med* 2020;2020:5630838 <https://doi.org/10.1155/2020/5630838>
- 9 Momose Y, Maeda-Yamamoto M, Nabetani H. Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans. *Int J Food Sci Nutr* 2016;67(6):606-13 <https://doi.org/10.1080/09637486.2016.1196655>
- 10 Xu R, Yang K, Li S, Dai M, Chen G. Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. *Nutr J* 2020;19(1):48 <https://doi.org/10.1186/s12937-020-00557-5>
- 11 Khan N, Mukhtar H. Tea and health: studies in humans. *Curr Pharm Des* 2013;19(34):6141-7 <https://doi.org/10.2174/1381612811319340008>
- 12 Lin Y, Shi D, Su B, Wei J, GÄfman MA, Sedanur MM et al. The effect of green tea supplementation on obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. *Phytother Res* 2020 <https://doi.org/10.1002/ptr.6697>
- 13 Abe SK, Inoue M. Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence. *Eur J Clin Nutr* 2020 <https://doi.org/10.1038/s41430-020-00710-7>

- 14 Menegazzi M, Campagnari R, Bertoldi M, Crupi R, Di PR, Cuzzocrea S. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? *Int J Mol Sci* 2020;21(14) <https://doi.org/10.3390/ijms21145171>
- 15 Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Front Immunol* 2020;11:1708 <https://doi.org/10.3389/fimmu.2020.01708>
- 16 Wessels I, Rolles B, Rink L. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. *Front Immunol* 2020;11:1712 <https://doi.org/10.3389/fimmu.2020.01712>
- 17 Alschuler L, Weil A, Horwitz R, Stamets P, Chiasson AM, Crocker R et al. Integrative considerations during the COVID-19 pandemic. *Explore (NY)* 2020;16(6):354-6 <https://doi.org/10.1016/j.explore.2020.03.007>
- 18 Coffee, tea, mate, methylxanthines and methylglyoxal. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 27 February to 6 March 1990. *IARC Monogr Eval Carcinog Risks Hum* 1991;51:1-513
- 19 Yukio Kosugi. Green tea consumption. *World Green Tea Association Available at: <https://www.o-cha.net/english/teacha/distribution/greentea3.html>* (accessed January 10, 2020)
- 20 Tea Research and Extension Station. Taiwan Tea Industry. <https://www.tres.gov.tw/en/ws.php?id=1000> (accessed January 10, 2020)
- 21 INTERGOVERNMENTAL GROUP ON TEA TWENTY-THIRD SESSION. Emerging Trends in Tea Consumption: Informing a Generic Promotion Process. <http://www.fao.org/economic/est/est-commodities/tea/tea-meetings/tea23/en/> 2018 (accessed January 10, 2020)
- 22 INTERGOVERNMENTAL GROUP ON TEA. CURRENT MARKET SITUATION AND MEDIUM TERM OUTLOOK . <http://www.fao.org/economic/est/est-commodities/tea/tea-meetings/tea23/en/> 2018 (accessed January 10, 2020)
- 23 Commodity Trade Statistics Database|. United Nations Statistics Division. http://data.un.org/Data.aspx?d=ComTrade&f=_11Code%3A10 2016 (accessed January 10, 2020)
- 24 Worldometers info. Coronavirus update. Available at: <https://www.worldometers.info/coronavirus/>, 2020;
- 25 Urashima M, Otani K, Hasegawa Y, Akutsu T. BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study. *Int J Environ Res Public Health* 2020;17(15) <https://doi.org/10.3390/ijerph17155589>
- 26 Klinger D, Blass I, Rappoport N, Linial M. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis. *Vaccines (Basel)* 2020;8(3) <https://doi.org/10.3390/vaccines8030378>

- 27 Madan M, Pahuja S, Mohan A, Pandey RM, Madan K, Hadda V et al. TB infection and BCG vaccination: are we protected from COVID-19? *Public Health* 2020;185:91-2 <https://doi.org/10.1016/j.puhe.2020.05.042>
- 28 World Bank. Population density (people per sq. km of land area). <https://data.worldbank.org/indicator/EN.POP.DNST> 2019 (accessed January 10, 2020)
- 29 worldbank.org. Population ages 65 and above (% of total population) . <https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS> 2019 (accessed January 10, 2020)
- 30 World Bank. Urban population (% of total population). <https://data.worldbank.org/indicator/SP.URB.TOTL.IN.ZS> Accessed 2019 (accessed January 10, 2020)
- 31 UN. United Nations Development Program. Human Development Reports (2019). <http://hdr.undp.org/en/content/2019-human-development-index-ranking> 2019 (accessed January 10, 2020)
- 32 Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *Proc Natl Acad Sci U S A* 2020;117(30):17720-6 <https://doi.org/10.1073/pnas.2008410117>
- 33 Tukey J. Exploratory data analysis. .Reading, Mass: Addison-Wesley Pub. Co.; 1977; 1977.
- 34 Hellwig MD, Maia A. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. *Int J Antimicrob Agents* 2021;57(1):106248 <https://doi.org/10.1016/j.ijantimicag.2020.106248>
- 35 Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020;178:104787 <https://doi.org/10.1016/j.antiviral.2020.104787>
- 36 Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. *Ann Clin Microbiol Antimicrob* 2020;19(1):23 <https://doi.org/10.1186/s12941-020-00368-w>
- 37 World Health Organization. (WHO) PCT Databank. WHO. https://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en 2020 (accessed January 10, 2020)
- 38 Aguiar M, Stollenwerk N. Condition-specific mortality risk can explain differences in COVID-19 case fatality ratios around the globe. *Public Health* 2020;188:18-20 <https://doi.org/10.1016/j.puhe.2020.08.021>
- 39 Hajian TK. Methodological issues of confounding in analytical epidemiologic studies. *Caspian J Intern Med* 2012;3(3):488-95 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755849/>
- 40 Furushima D, Nishimura T, Takuma N, Iketani R, Mizuno T, Matsui Y et al. Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial. *Nutrients* 2019;12(1) <https://doi.org/10.3390/nu12010004>

Supplementary materials

Table S1.

Countries included in the analysis of correlation using Spearman Rank Correlation.

Country	Green tea consumption (per capita, g)	COVID-19 Cases /MLN (8 month after onset)	COVID-19 Deaths/ MLN (8 month after onset)	Population (values used for calculations)
1 China	320.0	59.21	3.22	1439323776
2 Indonesia	200.0	1670.19	54.87	274061093
3 Japan	650.0	717.63	13.02	126402156
4 Vietnam	380.0	12.88	0.36	97501966
5 Algeria	332.2	1538.32	48.96	43995401
6 Afghanistan	718.7	1158.46	43.80	39086286
7 Morocco	1782.9	8299.05	135.52	36991599
8 Uzbekistan	524.7	2145.06	18.00	33558454
9 Niger	212.1	65.11	3.08	24358512
10 Taiwan	750.0	25.06	0.29	23824956
11 Burkina Faso	166.9	128.68	3.24	21005152
12 Mali	605.4	259.90	8.60	20354106
13 Senegal	344.6	943.08	19.62	16822587
14 Guinea	219.0	995.97	5.76	13196163
15 Tunisia	247.4	7284.91	226.66	11841606
16 UAE	195.5	14455.35	51.95	9912524
17 Hong Kong	290.3	723.33	14.38	7508352
18 Libya	451.2	13615.69	195.40	6888524
19 Denmark	177.7	9643.11	128.88	5796058
20 Mauritania	3393.1	3433.41	86.05	4671450
21 Mongolia	552.1	449.82	0.61	3287964
1 USA	31.0	26859.47	695.35	331367517
2 Pakistan	14.1	1610.06	33.45	221671477
3 Brazil	1.6	27010.60	767.73	212842596
4 Nigeria	17.0	322.64	5.65	207054356
5 Russia	84.4	13040.77	224.97	145946376
6 Mexico	2.7	7791.35	762.80	129184522
7 Ethiopia	0.0	984.94	15.20	115473464
8 Philippines	19.2	3666.91	70.29	109850251
9 Egypt	3.9	1063.45	62.01	102685534
10 Turkey	3.0	13564.04	138.50	84507634
11 Iran	4.1	6683.62	383.89	84191615
12 Germany	93.0	5721.04	123.56	83834622
13 Thailand	50.1	54.85	0.86	69833165

14	UK	47.8	16173.73	702.57	67953144
15	France	98.0	18914.47	548.00	65300897
16	Italy	21.5	9343.65	623.71	60444825
17	Colombia	2.5	23639.28	671.25	50983652
18	Spain	84.8	27186.83	786.02	46758226
19	Sudan	5.3	513.72	32.36	44033287
20	Ukraine	57.6	14301.76	250.69	43683007
21	Poland	40.1	16952.91	239.91	37838691
22	Canada	102.4	6766.73	276.06	37803923
23	Saudi Arabia	61.9	10099.32	161.11	34913354
24	Peru	4.5	28345.75	1065.78	33056487
25	Angola	8.2	572.71	13.28	33046107
26	Malaysia	46.7	1091.93	8.35	32442628
27	Ghana	15.4	1641.02	10.36	31190307
28	Madagascar	0.4	623.37	9.02	27818152
29	Cameroon	4.9	894.16	16.31	26664138
30	Ivory Coast	40.7	798.48	5.02	26495233
31	Australia	79.0	1080.90	35.49	25554723
32	Malawi	1.0	446.19	11.71	19218201
33	Romania	18.3	17396.47	442.93	19212864
34	Chile	23.3	27577.91	769.74	19146844
35	Kazakhstan	59.0	6464.61	103.68	18818299
36	Zambia	1.2	1001.55	19.97	18475317
37	Ecuador	1.7	10551.28	735.69	17692261
38	Syria	23.7	731.07	46.48	17576878
39	Netherlands	104.8	22779.52	453.21	17142061
40	Cambodia	10.2	18.14	0.00	16761610
41	Zimbabwe	2.4	1973.33	58.98	14902728
42	Rwanda	3.7	451.36	3.61	13009703
43	Benin	46.0	260.02	3.61	12179833
44	Bolivia	4.1	12328.77	763.43	11702383
45	Belgium	33.8	40366.19	1063.10	11599139
46	Dominican Republic	5.2	18372.21	228.37	10868152
47	Czechia	50.9	39287.57	515.37	10712751
48	Greece	50.7	5263.39	71.93	10413243
49	Portugal	10.1	19273.96	304.48	10191005
50	Azerbaijan	12.1	8860.48	109.00	10156225
51	Sweden	40.0	14141.80	601.81	10111092
52	Honduras	2.8	10627.89	289.63	9933487
53	Hungary	21.7	15810.33	339.80	9655649
54	Belarus	59.1	12489.30	112.93	9448730
55	Israel	15.9	36487.60	311.39	9197590
56	Austria	55.2	15414.60	148.62	9016062
57	Serbia	0.7	10008.59	117.98	8730602
58	Switzerland	39.3	21035.42	285.12	8666478
59	Togo	33.3	372.28	7.82	8313592

60	Sierra Leone	5.4	313.38	9.37	8006379
61	Paraguay	7.4	11251.76	240.60	7148749
62	Bulgaria	3.1	14160.66	306.99	6938307
63	Lebanon	10.2	14210.15	109.83	6819561
64	Nicaragua	2.8	934.46	25.30	6639152
65	Kyrgyzstan	108.2	10752.92	189.64	6543898
66	El Salvador	5.2	6150.30	175.90	6492369
67	Singapore	34.6	9878.90	4.78	5858949
68	Finland	30.9	3309.96	65.86	5542355
69	Slovakia	33.6	15890.97	93.40	5460145
70	Norway	30.3	4158.65	51.94	5429172
71	Oman	127.0	23657.67	266.09	5129838
72	Costa Rica	6.6	24612.01	309.24	5102793
73	New Zealand	23.1	402.43	5.00	5002100
74	Ireland	86.8	13466.40	397.13	4948020
75	CAR	0.4	1024.33	13.00	4845103
76	Panama	0.3	33890.77	663.94	4327225
77	Kuwait	55.7	29726.19	179.35	4282183
78	Croatia	35.2	20856.39	263.88	4100375
79	Uruguay	6.3	1210.58	19.56	3476006
80	Bosnia and Herzegovina	12.1	23423.84	657.03	3276875

Countries in the subgroups with 'high' (above 150 g/per capita) and 'low' estimated green tea consumption are numbered separately; countries in each subgroup are ranked by population.

Except China, Vietnam, Japan, Indonesia and Taiwan, estimates of per capita green tea consumption are based on the differences of annual import and export of green tea (see Methods). Most of these values are for the year 2016. For several countries (including Yemen, South Africa, Serbia) an average of differences between green tea import and export for two sequential years was calculated to check if it is positive and a country should be included in the group with the 'known' per capita green tea consumption. Yemen and South Africa were excluded from the final list presented here because the average balance was negative. Values of population, used for calculations are from the single source and date ('Worldometer', September 2020).

Table S2.

A. Higher per capita green tea consumption is associated with lower COVID-19 morbidity.

Regression Coefficient					Lower	Upper	VIF (Variance	
	Estimate	SE	t(cal)	P(T<=t(cal))	95%	95%	Inflation Factor)	
b0	2.139633	0.234946	9.1069164	*** (P<=0.001)	1.34E-14	1.673206	2.60606	
b1:X1	-0.00067	0.000287	-2.321013	* (P<=0.05)	0.02242481	-0.00124	-9.65E-05	1.00669
b2:X2	-0.00012	6.66E-05	-1.877445	N.S. (P>0.05)	0.06352517	-0.00026	7.18E-06	1.075085
b3:X3	0.017188	0.011256	1.5270234	N.S. (P>0.05)	0.13007786	-0.00516	0.039534	1.364101
b4:X4	0.02038	0.003988	5.1105683	*** (P<=0.001)	1.66E-06	0.012463	0.028296	1.443678

Standard Regression Coefficient

	Estimate	SE		
b1:X1	-0.18913	0.081484	X1	green tea consumption
b2:X2	-0.15809	0.084207	X2	population density
b3:X3	0.144842	0.094852	X3	%population aged above 65
b4:X4	0.498688	0.09758	X4	urban population % of total
			Y	Log(cases/million) _{8-month}

Main values obtained in the multiple regression model with Log(cases/million)_{8-month} as dependent variable and four independent variables are shown. N=100 (countries listed in Table S1, excluding Mauritania).

B. Higher per capita green tea consumption is associated with lower COVID-19 mortality.

Regression Coefficient					Lower	Upper	VIF (Variance	
	Estimate	SE	t(cal)	P(T<=t(cal))	95%	95%	Inflation Factor)	
b0	0.656052	0.251973	2.6036558	* (P<=0.05)	0.01071966	0.155753	1.156351	
b1:X1	-0.00078	0.0003	-2.609203	* (P<=0.05)	0.0105592	-0.00138	-0.00019	1.007759
b2:X2	-0.00023	6.94E-05	-3.289652	** (P<=0.01)	0.00141276	-0.00037	-9.06E-05	1.076687
b3:X3	0.025541	0.011739	2.1757647	* (P<=0.05)	0.03208023	0.002233	0.048849	1.35754
b4:X4	0.016141	0.004241	3.805876	*** (P<=0.001)	0.0002515	0.00772	0.024561	1.439814

Standard Regression Coefficient

	Estimate	SE		
b1:X1	-0.21781	0.083476	X1	green tea consumption
b2:X2	-0.28384	0.086284	X2	population density
b3:X3	0.210801	0.096886	X3	%population aged above 65
b4:X4	0.379746	0.099779	X4	urban population % of total
			Y	Log(deaths/million) _{8-month}

Main values obtained in the multiple regression model with Log(deaths/million)_{8-month} as dependent variable and four independent variables are shown. N=99 (countries listed in Table S1, excluding Mauritania and Cambodia).

In these and the following Tables the values are copy-pasted from 'KyPlot' (used for multiple regression analysis).

Table S3.

A. Higher per capita green tea consumption is still associated with lower COVID-19 morbidity in the model accounting for Human Development Index (HDI).

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	1.299701	0.410205	3.1684225	** (P<=0.01)	0.00206818	0.485231	2.114172	
b1:X1	-0.00066	0.00028	-2.352308	* (P<=0.05)	0.02074334	-0.00121	-1.03E-04	1.006838
b2:X2	-0.00013	6.49E-05	-1.993778	* (P<=0.05)	0.04907418	-0.00026	-5.36E-07	1.075888
b3:X3	-0.00863	0.015156	-0.569096	N.S. (P>0.05)	0.5706482	-0.03872	0.021467	2.60554
b4:X4	0.011593	0.00527	2.1997605	* (P<=0.05)	0.0302754	0.001129	0.022057	2.656559
b5:X5	2.262758	0.91704	2.4674591	* (P<=0.05)	0.01541704	0.441954	4.083561	4.741674

Standard Regression Coefficient

	Estimate	SE		
b1:X1	-0.18675	0.079392		X1 green tea consumption
b2:X2	-0.16363	0.082069		X2 population density
b3:X3	-0.07268	0.127715		X3 %population aged above 65
b4:X4	0.283681	0.12896		X4 urban population % of total
b5:X5	0.425119	0.17229		X5 HDI
				Y Log(cases/million) _{8-month}

Main values obtained in the multiple regression model with Log(cases/million)_{8-month} as dependent variable and five independent variables are shown. N=100 (the same as in Table S2 A).

B. Higher per capita green tea consumption is still associated with lower COVID-19 mortality in the model accounting for Human Development Index (HDI).

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	0.054116	0.435535	0.1242522	N.S. (P>0.05)	0.90138373	-0.81077	0.919002	
b1:X1	-0.00078	0.000297	-2.62E+00	* (P<=0.05)	0.01020825	-0.00137	-0.00019	1.007814
b2:X2	-0.00023	6.88E-05	-3.360932	** (P<=0.01)	0.00112832	-0.00037	-9.46E-05	1.077296
b3:X3	0.006836	0.016069	0.4254099	N.S. (P>0.05)	0.67152071	-0.02507	0.038745	2.593504
b4:X4	0.009634	0.005703	1.6890875	N.S. (P>0.05)	0.09455285	-0.00169	0.02096	2.655167
b5:X5	1.644549	0.975253	1.6862791	N.S. (P>0.05)	0.09509418	-0.29211	3.581209	4.72475

Standard Regression Coefficient

	Estimate	SE		
b1:X1	-0.21678	0.082672		X1 green tea consumption
b2:X2	-0.28727	0.085474		X2 population density
b3:X3	0.056418	0.132621		X3 %population aged above 65
b4:X4	0.226655	0.134188		X4 urban population % of total
b5:X5	0.301847	0.179002		X5 HDI
				Y Log(deaths/million) _{8-month}

Main values obtained in the multiple regression model with Log(deaths/million)_{8-month} as dependent variable and five independent variables are shown. N=99 (the same as in Table S2 B).

Table S4.

A. Exclusion of countries with mass administration of ivermectin appears to increase the strength of the association between per capita green tea consumption and COVID-19 morbidity.

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	2.416337	0.28836	8.3795856	*** (P<=0.001)	1.34E-12	1.842591	2.990083	
b1:X1	-0.00077	0.000301	-2.543183	* (P<=0.05)	0.01288754	-0.00137	-0.00017	1.015859
b2:X2	-0.00012	6.87E-05	-1.799757	N.S. (P>0.05)	0.07562258	-0.00026	1.30E-05	1.078535
b3:X3	0.00807	0.01215	0.6642211	N.S. (P>0.05)	0.50843524	-0.0161	0.032245	1.251498
b4:X4	0.018918	0.004494	4.2099507	*** (P<=0.001)	6.57E-05	0.009977	0.027858	1.328393

Standard Regression Coefficient

	Estimate	SE		
b1:X1	-0.23806	0.093607	X1	green tea consumption
b2:X2	-0.17359	0.096451	X2	population density
b3:X3	0.069011	0.103898	X3	%population aged above 65
b4:X4	0.450642	0.107042	X4	urban population % of total
			Y	Log(cases/million) _{8-month}

Main values obtained in multiple regression model with $\text{Log}(\text{cases/million})_{8\text{-month}}$ as dependent variable and four independent variables are shown. N= 86 (as in Table S2 A, but excluding countries with mass drug administration of ivermectin¹).

B. Exclusion of countries with mass administration of ivermectin appears to increase the strength of the association between per capita green tea consumption and COVID-19 mortality.

Regression Coefficient

	Estimate	SE	t(cal)		P(T<=t(cal))	Lower 95%	Upper 95%	VIF (Variance Inflation Factor)
b0	0.995125	0.307901	3.2319609	** (P<=0.01)	0.00178623	0.382382	1.607868	
b1:X1	-0.00093	0.00031	-2.994489	** (P<=0.01)	0.00365727	-0.00154	-0.00031	1.0188
b2:X2	-0.00023	7.04E-05	-3.225352	** (P<=0.01)	0.00182307	-0.00037	-8.70E-05	1.081253
b3:X3	0.013841	0.012442	1.1124154	N.S. (P>0.05)	0.26929123	-0.01092	0.038601	1.238439
b4:X4	0.014528	0.00474	3.0648789	** (P<=0.01)	0.00296827	0.005095	0.02396	1.31987

Standard Regression Coefficient

	Estimate	SE		
b1:X1	-0.28244	0.094319	X1	green tea consumption
b2:X2	-0.3134	0.097167	X2	population density
b3:X3	0.11568	0.10399	X3	%population aged above 65
b4:X4	0.329028	0.107354	X4	urban population % of total
			Y	Log(deaths/million) _{8-month}

Main values obtained in multiple regression model with $\text{Log}(\text{deaths/million})_{8\text{-month}}$ as dependent variable and four independent variables are shown. N= 85 (as in Table S2 B, but excluding countries with mass drug administration of ivermectin¹).

¹ Countries with mass drug administration of ivermectin: Angola, Benin, Burkina Faso, Cameroon, Ivory Coast, CAR, Ethiopia, Ghana, Niger, Nigeria, Senegal, Sierra Leone, Sudan, Malaysia.